Registry following people newly evaluated for light chain amyloidosis across Europe
Collects information and samples from adults with AL amyloidosis to study the disease.
Plain-language title generated from the registry record
Registry title: A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)
Key facts
- Where
- Utrecht, NetherlandsSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults newly diagnosed with systemic AL amyloidosis who have not yet been treated and will be followed at a participating center.
- Age
- 18 Years to 99 Years
- Sex
- All sexes can join.
- Disease stage
- Diagnosis of systemic AL amyloidosis.
- Earlier treatment
- Must not have had any treatment for AL amyloidosis before (treatment-naïve).
Main reasons for not taking part
- Amyloidosis that is not AL amyloidosis
- Previous treatment for AL amyloidosis
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT06205953, who can take part
Where in Netherlands
- UMC Utrecht, dept Hematology, Amyloid Expertise Center, Utrecht, HeidelberglaanUtrecht, NetherlandsContact: Monique Minnema, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Trial code
- NCT06205953
- Record updated
- 16 April 2026
- Original description
A prospective patients' registry collecting all new cases of AL amyloidosis evaluated at referral Centers from across Europe and a sample sharing network will be created to study mechanisms of the disease through the use of advanced molecular technologies and big data analysis tools.Read full original descriptionShow less
Bonding Molecular Genotyping and Phenotyping to Outcome Measures in AL Amyloidosis: A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)
A prospective patients' registry collecting all new cases of AL amyloidosis evaluated at referral Centers from across Europe and a sample sharing network will be created to study mechanisms of the disease through the use of advanced molecular technologies and big data analysis tools.
Inclusion: diagnosis of systemic AL amyloidosis; treatment-naïve; age ≥18 years; ability to understand and willingness to sign an informed consent; planned follow-up at participating center.
Exclusion: previous treatment for AL amyloidosis; non-AL amyloidosis.